nodes	percent_of_prediction	percent_of_DWPC	metapath
Zidovudine—ABCC5—Cisplatin—testicular cancer	0.0978	0.128	CbGbCtD
Zidovudine—UGT2B7—Epirubicin—testicular cancer	0.067	0.0879	CbGbCtD
Zidovudine—CYP2A6—Ifosfamide—testicular cancer	0.0561	0.0736	CbGbCtD
Zidovudine—ABCG2—Dactinomycin—testicular cancer	0.044	0.0577	CbGbCtD
Zidovudine—SLC22A2—Vinblastine—testicular cancer	0.0373	0.049	CbGbCtD
Zidovudine—SLC22A2—Cisplatin—testicular cancer	0.0342	0.0449	CbGbCtD
Zidovudine—SLC22A11—Methotrexate—testicular cancer	0.0328	0.043	CbGbCtD
Zidovudine—SLC22A7—Methotrexate—testicular cancer	0.0312	0.0409	CbGbCtD
Zidovudine—ABCC4—Methotrexate—testicular cancer	0.0305	0.04	CbGbCtD
Zidovudine—ABCG2—Carboplatin—testicular cancer	0.0296	0.0388	CbGbCtD
Zidovudine—CYP2C8—Ifosfamide—testicular cancer	0.0277	0.0363	CbGbCtD
Zidovudine—ABCG2—Cisplatin—testicular cancer	0.0253	0.0331	CbGbCtD
Zidovudine—ABCG2—Etoposide—testicular cancer	0.0248	0.0326	CbGbCtD
Zidovudine—CYP2C19—Ifosfamide—testicular cancer	0.0232	0.0304	CbGbCtD
Zidovudine—CYP2C9—Ifosfamide—testicular cancer	0.0193	0.0253	CbGbCtD
Zidovudine—SLC22A8—Methotrexate—testicular cancer	0.0191	0.025	CbGbCtD
Zidovudine—ABCG2—Doxorubicin—testicular cancer	0.0169	0.0222	CbGbCtD
Zidovudine—ABCG2—Methotrexate—testicular cancer	0.0164	0.0215	CbGbCtD
Zidovudine—ABCB1—Dactinomycin—testicular cancer	0.0159	0.0208	CbGbCtD
Zidovudine—SLC22A6—Methotrexate—testicular cancer	0.0133	0.0174	CbGbCtD
Zidovudine—CYP2C8—Etoposide—testicular cancer	0.0132	0.0173	CbGbCtD
Zidovudine—ALB—Methotrexate—testicular cancer	0.0113	0.0148	CbGbCtD
Zidovudine—CYP3A4—Ifosfamide—testicular cancer	0.0112	0.0147	CbGbCtD
Zidovudine—ABCB1—Vinblastine—testicular cancer	0.00994	0.013	CbGbCtD
Zidovudine—CYP2C9—Cisplatin—testicular cancer	0.00939	0.0123	CbGbCtD
Zidovudine—ABCB1—Cisplatin—testicular cancer	0.00911	0.0119	CbGbCtD
Zidovudine—ABCB1—Etoposide—testicular cancer	0.00895	0.0117	CbGbCtD
Zidovudine—ABCB1—Doxorubicin—testicular cancer	0.00611	0.00801	CbGbCtD
Zidovudine—CYP3A4—Vinblastine—testicular cancer	0.00595	0.00781	CbGbCtD
Zidovudine—ABCB1—Methotrexate—testicular cancer	0.00592	0.00776	CbGbCtD
Zidovudine—CYP3A4—Etoposide—testicular cancer	0.00536	0.00703	CbGbCtD
Zidovudine—TERT—embryo—testicular cancer	0.00498	0.183	CbGeAlD
Zidovudine—CYP3A4—Doxorubicin—testicular cancer	0.00366	0.0048	CbGbCtD
Zidovudine—TERT—female gonad—testicular cancer	0.00275	0.101	CbGeAlD
Zidovudine—TERT—testis—testicular cancer	0.00244	0.0895	CbGeAlD
Zidovudine—TK1—female gonad—testicular cancer	0.00189	0.0694	CbGeAlD
Zidovudine—TK1—testis—testicular cancer	0.00168	0.0616	CbGeAlD
Zidovudine—SLC28A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0014	0.0614	CbGpPWpGaD
Zidovudine—CYP2A6—seminal vesicle—testicular cancer	0.00129	0.0474	CbGeAlD
Zidovudine—TK1—lymph node—testicular cancer	0.00122	0.0446	CbGeAlD
Zidovudine—SLC29A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00114	0.05	CbGpPWpGaD
Zidovudine—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00109	0.0479	CbGpPWpGaD
Zidovudine—SLC29A2—lymph node—testicular cancer	0.00101	0.0369	CbGeAlD
Zidovudine—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00099	0.0435	CbGpPWpGaD
Zidovudine—UGT2B7—testis—testicular cancer	0.000937	0.0344	CbGeAlD
Zidovudine—SLC22A7—testis—testicular cancer	0.000891	0.0327	CbGeAlD
Zidovudine—ABCC5—female gonad—testicular cancer	0.000844	0.031	CbGeAlD
Zidovudine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000832	0.0366	CbGpPWpGaD
Zidovudine—ABCC5—NRF2 pathway—SLC2A6—testicular cancer	0.00083	0.0365	CbGpPWpGaD
Zidovudine—TERT—Telomere Maintenance—H2AFZ—testicular cancer	0.000826	0.0363	CbGpPWpGaD
Zidovudine—TERT—formation of the beta-catenin:TCF transactivating complex—H2AFZ—testicular cancer	0.000757	0.0332	CbGpPWpGaD
Zidovudine—ABCC5—testis—testicular cancer	0.000749	0.0275	CbGeAlD
Zidovudine—SLC28A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00071	0.0312	CbGpPWpGaD
Zidovudine—ABCG2—seminal vesicle—testicular cancer	0.000703	0.0258	CbGeAlD
Zidovudine—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000695	0.0305	CbGpPWpGaD
Zidovudine—TERT—Chromosome Maintenance—H2AFZ—testicular cancer	0.000688	0.0302	CbGpPWpGaD
Zidovudine—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.000658	0.0289	CbGpPWpGaD
Zidovudine—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.000612	0.0269	CbGpPWpGaD
Zidovudine—ABCC4—female gonad—testicular cancer	0.000585	0.0215	CbGeAlD
Zidovudine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000579	0.0254	CbGpPWpGaD
Zidovudine—SLC29A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000579	0.0254	CbGpPWpGaD
Zidovudine—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.000575	0.0253	CbGpPWpGaD
Zidovudine—ABCC5—lymph node—testicular cancer	0.000543	0.0199	CbGeAlD
Zidovudine—ALB—testis—testicular cancer	0.000536	0.0197	CbGeAlD
Zidovudine—ABCC4—testis—testicular cancer	0.000519	0.0191	CbGeAlD
Zidovudine—SLC22A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000496	0.0218	CbGpPWpGaD
Zidovudine—TERT—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.00045	0.0198	CbGpPWpGaD
Zidovudine—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00045	0.0198	CbGpPWpGaD
Zidovudine—ABCG2—female gonad—testicular cancer	0.000413	0.0152	CbGeAlD
Zidovudine—ALB—lymph node—testicular cancer	0.000389	0.0143	CbGeAlD
Zidovudine—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	0.000383	0.0168	CbGpPWpGaD
Zidovudine—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000378	0.0166	CbGpPWpGaD
Zidovudine—CYP2C8—testis—testicular cancer	0.000377	0.0138	CbGeAlD
Zidovudine—ABCC4—lymph node—testicular cancer	0.000376	0.0138	CbGeAlD
Zidovudine—ABCB1—embryo—testicular cancer	0.000369	0.0136	CbGeAlD
Zidovudine—ABCG2—testis—testicular cancer	0.000366	0.0135	CbGeAlD
Zidovudine—TERT—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.000363	0.0159	CbGpPWpGaD
Zidovudine—TERT—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.000351	0.0154	CbGpPWpGaD
Zidovudine—ABCB1—seminal vesicle—testicular cancer	0.000347	0.0127	CbGeAlD
Zidovudine—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	0.000333	0.0146	CbGpPWpGaD
Zidovudine—TERT—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000326	0.0143	CbGpPWpGaD
Zidovudine—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000316	0.0139	CbGpPWpGaD
Zidovudine—TERT—Signaling by Wnt—H2AFZ—testicular cancer	0.000269	0.0118	CbGpPWpGaD
Zidovudine—ABCC5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000266	0.0117	CbGpPWpGaD
Zidovudine—ABCG2—lymph node—testicular cancer	0.000266	0.00976	CbGeAlD
Zidovudine—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000263	0.0116	CbGpPWpGaD
Zidovudine—SLC22A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000252	0.0111	CbGpPWpGaD
Zidovudine—ABCB1—gonad—testicular cancer	0.000251	0.00921	CbGeAlD
Zidovudine—TERT—Cell Cycle—MAD1L1—testicular cancer	0.000251	0.011	CbGpPWpGaD
Zidovudine—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000229	0.01	CbGpPWpGaD
Zidovudine—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000224	0.00984	CbGpPWpGaD
Zidovudine—ABCB1—female gonad—testicular cancer	0.000204	0.00748	CbGeAlD
Zidovudine—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	0.0002	0.00878	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—INSL3—testicular cancer	0.000196	0.00861	CbGpPWpGaD
Zidovudine—UGT2B7—Biological oxidations—HPGDS—testicular cancer	0.000195	0.00856	CbGpPWpGaD
Zidovudine—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000192	0.00844	CbGpPWpGaD
Zidovudine—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000184	0.00809	CbGpPWpGaD
Zidovudine—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000182	0.00801	CbGpPWpGaD
Zidovudine—ABCB1—testis—testicular cancer	0.000181	0.00664	CbGeAlD
Zidovudine—TERT—Cell Cycle—H2AFZ—testicular cancer	0.000175	0.00767	CbGpPWpGaD
Zidovudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000168	0.00739	CbGpPWpGaD
Zidovudine—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000164	0.00721	CbGpPWpGaD
Zidovudine—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00016	0.00704	CbGpPWpGaD
Zidovudine—Rash—Dactinomycin—testicular cancer	0.000153	0.000818	CcSEcCtD
Zidovudine—Decreased appetite—Etoposide—testicular cancer	0.000153	0.000816	CcSEcCtD
Zidovudine—Diarrhoea—Ifosfamide—testicular cancer	0.000152	0.000813	CcSEcCtD
Zidovudine—Pancytopenia—Doxorubicin—testicular cancer	0.000152	0.000813	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000152	0.00081	CcSEcCtD
Zidovudine—Body temperature increased—Cisplatin—testicular cancer	0.000152	0.00081	CcSEcCtD
Zidovudine—Fatigue—Etoposide—testicular cancer	0.000152	0.000809	CcSEcCtD
Zidovudine—Neuropathy peripheral—Epirubicin—testicular cancer	0.000152	0.000809	CcSEcCtD
Zidovudine—Stomatitis—Epirubicin—testicular cancer	0.000151	0.000804	CcSEcCtD
Zidovudine—Jaundice—Epirubicin—testicular cancer	0.000151	0.000804	CcSEcCtD
Zidovudine—Constipation—Etoposide—testicular cancer	0.000151	0.000803	CcSEcCtD
Zidovudine—Pain—Etoposide—testicular cancer	0.000151	0.000803	CcSEcCtD
Zidovudine—Dysuria—Doxorubicin—testicular cancer	0.00015	0.000801	CcSEcCtD
Zidovudine—Neutropenia—Doxorubicin—testicular cancer	0.00015	0.000801	CcSEcCtD
Zidovudine—Hepatitis—Methotrexate—testicular cancer	0.000148	0.000791	CcSEcCtD
Zidovudine—Sweating—Epirubicin—testicular cancer	0.000148	0.000791	CcSEcCtD
Zidovudine—Pollakiuria—Doxorubicin—testicular cancer	0.000148	0.000791	CcSEcCtD
Zidovudine—Haematuria—Epirubicin—testicular cancer	0.000147	0.000787	CcSEcCtD
Zidovudine—Dizziness—Ifosfamide—testicular cancer	0.000147	0.000786	CcSEcCtD
Zidovudine—Pharyngitis—Methotrexate—testicular cancer	0.000147	0.000785	CcSEcCtD
Zidovudine—Urinary tract disorder—Methotrexate—testicular cancer	0.000147	0.000782	CcSEcCtD
Zidovudine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000146	0.00078	CcSEcCtD
Zidovudine—Epistaxis—Epirubicin—testicular cancer	0.000146	0.000778	CcSEcCtD
Zidovudine—Urethral disorder—Methotrexate—testicular cancer	0.000145	0.000776	CcSEcCtD
Zidovudine—Weight decreased—Doxorubicin—testicular cancer	0.000145	0.000775	CcSEcCtD
Zidovudine—Sinusitis—Epirubicin—testicular cancer	0.000145	0.000774	CcSEcCtD
Zidovudine—Feeling abnormal—Etoposide—testicular cancer	0.000145	0.000773	CcSEcCtD
Zidovudine—Nausea—Dactinomycin—testicular cancer	0.000144	0.00077	CcSEcCtD
Zidovudine—Agranulocytosis—Epirubicin—testicular cancer	0.000144	0.00077	CcSEcCtD
Zidovudine—Gastrointestinal pain—Etoposide—testicular cancer	0.000144	0.000768	CcSEcCtD
Zidovudine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000142	0.000757	CcSEcCtD
Zidovudine—Vomiting—Ifosfamide—testicular cancer	0.000142	0.000756	CcSEcCtD
Zidovudine—Rash—Ifosfamide—testicular cancer	0.000141	0.000749	CcSEcCtD
Zidovudine—Dermatitis—Ifosfamide—testicular cancer	0.00014	0.000749	CcSEcCtD
Zidovudine—Erythema multiforme—Methotrexate—testicular cancer	0.00014	0.000748	CcSEcCtD
Zidovudine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.00014	0.000748	CcSEcCtD
Zidovudine—Urticaria—Etoposide—testicular cancer	0.00014	0.000746	CcSEcCtD
Zidovudine—Stomatitis—Doxorubicin—testicular cancer	0.00014	0.000744	CcSEcCtD
Zidovudine—Jaundice—Doxorubicin—testicular cancer	0.00014	0.000744	CcSEcCtD
Zidovudine—Rhinitis—Epirubicin—testicular cancer	0.000139	0.000742	CcSEcCtD
Zidovudine—Abdominal pain—Etoposide—testicular cancer	0.000139	0.000742	CcSEcCtD
Zidovudine—Body temperature increased—Etoposide—testicular cancer	0.000139	0.000742	CcSEcCtD
Zidovudine—Hepatitis—Epirubicin—testicular cancer	0.000139	0.000741	CcSEcCtD
Zidovudine—Asthenia—Cisplatin—testicular cancer	0.000138	0.000735	CcSEcCtD
Zidovudine—Pharyngitis—Epirubicin—testicular cancer	0.000138	0.000735	CcSEcCtD
Zidovudine—Cardiac disorder—Methotrexate—testicular cancer	0.000138	0.000734	CcSEcCtD
Zidovudine—Sweating—Doxorubicin—testicular cancer	0.000137	0.000732	CcSEcCtD
Zidovudine—Urinary tract disorder—Epirubicin—testicular cancer	0.000137	0.000731	CcSEcCtD
Zidovudine—Haematuria—Doxorubicin—testicular cancer	0.000136	0.000728	CcSEcCtD
Zidovudine—Connective tissue disorder—Epirubicin—testicular cancer	0.000136	0.000728	CcSEcCtD
Zidovudine—Urethral disorder—Epirubicin—testicular cancer	0.000136	0.000726	CcSEcCtD
Zidovudine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000135	0.000722	CcSEcCtD
Zidovudine—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000135	0.00593	CbGpPWpGaD
Zidovudine—Epistaxis—Doxorubicin—testicular cancer	0.000135	0.00072	CcSEcCtD
Zidovudine—Sinusitis—Doxorubicin—testicular cancer	0.000134	0.000716	CcSEcCtD
Zidovudine—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000134	0.00587	CbGpPWpGaD
Zidovudine—Mediastinal disorder—Methotrexate—testicular cancer	0.000134	0.000713	CcSEcCtD
Zidovudine—Agranulocytosis—Doxorubicin—testicular cancer	0.000134	0.000712	CcSEcCtD
Zidovudine—Chills—Methotrexate—testicular cancer	0.000133	0.00071	CcSEcCtD
Zidovudine—Nausea—Ifosfamide—testicular cancer	0.000132	0.000706	CcSEcCtD
Zidovudine—Diarrhoea—Cisplatin—testicular cancer	0.000131	0.000701	CcSEcCtD
Zidovudine—Erythema multiforme—Epirubicin—testicular cancer	0.000131	0.0007	CcSEcCtD
Zidovudine—ABCB1—lymph node—testicular cancer	0.000131	0.00481	CbGeAlD
Zidovudine—Mental disorder—Methotrexate—testicular cancer	0.00013	0.000693	CcSEcCtD
Zidovudine—Malnutrition—Methotrexate—testicular cancer	0.000129	0.000689	CcSEcCtD
Zidovudine—Erythema—Methotrexate—testicular cancer	0.000129	0.000689	CcSEcCtD
Zidovudine—Cardiac disorder—Epirubicin—testicular cancer	0.000129	0.000687	CcSEcCtD
Zidovudine—Rhinitis—Doxorubicin—testicular cancer	0.000129	0.000687	CcSEcCtD
Zidovudine—Hepatitis—Doxorubicin—testicular cancer	0.000128	0.000685	CcSEcCtD
Zidovudine—Pharyngitis—Doxorubicin—testicular cancer	0.000128	0.00068	CcSEcCtD
Zidovudine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000127	0.000677	CcSEcCtD
Zidovudine—Dysgeusia—Methotrexate—testicular cancer	0.000126	0.000675	CcSEcCtD
Zidovudine—Asthenia—Etoposide—testicular cancer	0.000126	0.000673	CcSEcCtD
Zidovudine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000126	0.000673	CcSEcCtD
Zidovudine—Urethral disorder—Doxorubicin—testicular cancer	0.000126	0.000672	CcSEcCtD
Zidovudine—Mediastinal disorder—Epirubicin—testicular cancer	0.000125	0.000667	CcSEcCtD
Zidovudine—Back pain—Methotrexate—testicular cancer	0.000125	0.000666	CcSEcCtD
Zidovudine—Chills—Epirubicin—testicular cancer	0.000125	0.000664	CcSEcCtD
Zidovudine—Pruritus—Etoposide—testicular cancer	0.000125	0.000664	CcSEcCtD
Zidovudine—Vomiting—Cisplatin—testicular cancer	0.000122	0.000651	CcSEcCtD
Zidovudine—CYP2A6—Biological oxidations—HPGDS—testicular cancer	0.000122	0.00536	CbGpPWpGaD
Zidovudine—Mental disorder—Epirubicin—testicular cancer	0.000122	0.000649	CcSEcCtD
Zidovudine—Erythema multiforme—Doxorubicin—testicular cancer	0.000121	0.000648	CcSEcCtD
Zidovudine—Rash—Cisplatin—testicular cancer	0.000121	0.000646	CcSEcCtD
Zidovudine—Dermatitis—Cisplatin—testicular cancer	0.000121	0.000645	CcSEcCtD
Zidovudine—Erythema—Epirubicin—testicular cancer	0.000121	0.000645	CcSEcCtD
Zidovudine—Malnutrition—Epirubicin—testicular cancer	0.000121	0.000645	CcSEcCtD
Zidovudine—Diarrhoea—Etoposide—testicular cancer	0.00012	0.000642	CcSEcCtD
Zidovudine—Ill-defined disorder—Methotrexate—testicular cancer	0.00012	0.000639	CcSEcCtD
Zidovudine—Anaemia—Methotrexate—testicular cancer	0.000119	0.000637	CcSEcCtD
Zidovudine—Cardiac disorder—Doxorubicin—testicular cancer	0.000119	0.000636	CcSEcCtD
Zidovudine—Flatulence—Epirubicin—testicular cancer	0.000119	0.000635	CcSEcCtD
Zidovudine—Tension—Epirubicin—testicular cancer	0.000119	0.000633	CcSEcCtD
Zidovudine—Dysgeusia—Epirubicin—testicular cancer	0.000118	0.000631	CcSEcCtD
Zidovudine—Nervousness—Epirubicin—testicular cancer	0.000117	0.000626	CcSEcCtD
Zidovudine—Back pain—Epirubicin—testicular cancer	0.000117	0.000624	CcSEcCtD
Zidovudine—Malaise—Methotrexate—testicular cancer	0.000116	0.000621	CcSEcCtD
Zidovudine—Dizziness—Etoposide—testicular cancer	0.000116	0.000621	CcSEcCtD
Zidovudine—Muscle spasms—Epirubicin—testicular cancer	0.000116	0.00062	CcSEcCtD
Zidovudine—Vertigo—Methotrexate—testicular cancer	0.000116	0.000619	CcSEcCtD
Zidovudine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000116	0.000618	CcSEcCtD
Zidovudine—Leukopenia—Methotrexate—testicular cancer	0.000116	0.000617	CcSEcCtD
Zidovudine—Chills—Doxorubicin—testicular cancer	0.000115	0.000615	CcSEcCtD
Zidovudine—Nausea—Cisplatin—testicular cancer	0.000114	0.000609	CcSEcCtD
Zidovudine—TK1—Metabolism—HPGDS—testicular cancer	0.000114	0.00499	CbGpPWpGaD
Zidovudine—Cough—Methotrexate—testicular cancer	0.000113	0.000601	CcSEcCtD
Zidovudine—Mental disorder—Doxorubicin—testicular cancer	0.000113	0.0006	CcSEcCtD
Zidovudine—Ill-defined disorder—Epirubicin—testicular cancer	0.000112	0.000598	CcSEcCtD
Zidovudine—Convulsion—Methotrexate—testicular cancer	0.000112	0.000597	CcSEcCtD
Zidovudine—Vomiting—Etoposide—testicular cancer	0.000112	0.000597	CcSEcCtD
Zidovudine—Erythema—Doxorubicin—testicular cancer	0.000112	0.000597	CcSEcCtD
Zidovudine—Malnutrition—Doxorubicin—testicular cancer	0.000112	0.000597	CcSEcCtD
Zidovudine—Anaemia—Epirubicin—testicular cancer	0.000112	0.000596	CcSEcCtD
Zidovudine—Rash—Etoposide—testicular cancer	0.000111	0.000592	CcSEcCtD
Zidovudine—Dermatitis—Etoposide—testicular cancer	0.000111	0.000591	CcSEcCtD
Zidovudine—Headache—Etoposide—testicular cancer	0.00011	0.000588	CcSEcCtD
Zidovudine—Flatulence—Doxorubicin—testicular cancer	0.00011	0.000588	CcSEcCtD
Zidovudine—Myalgia—Methotrexate—testicular cancer	0.00011	0.000586	CcSEcCtD
Zidovudine—Chest pain—Methotrexate—testicular cancer	0.00011	0.000586	CcSEcCtD
Zidovudine—Arthralgia—Methotrexate—testicular cancer	0.00011	0.000586	CcSEcCtD
Zidovudine—Tension—Doxorubicin—testicular cancer	0.00011	0.000585	CcSEcCtD
Zidovudine—Dysgeusia—Doxorubicin—testicular cancer	0.00011	0.000584	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000109	0.000582	CcSEcCtD
Zidovudine—Malaise—Epirubicin—testicular cancer	0.000109	0.000581	CcSEcCtD
Zidovudine—Discomfort—Methotrexate—testicular cancer	0.000109	0.000579	CcSEcCtD
Zidovudine—Nervousness—Doxorubicin—testicular cancer	0.000109	0.000579	CcSEcCtD
Zidovudine—Vertigo—Epirubicin—testicular cancer	0.000109	0.000579	CcSEcCtD
Zidovudine—Syncope—Epirubicin—testicular cancer	0.000108	0.000578	CcSEcCtD
Zidovudine—Leukopenia—Epirubicin—testicular cancer	0.000108	0.000577	CcSEcCtD
Zidovudine—Back pain—Doxorubicin—testicular cancer	0.000108	0.000577	CcSEcCtD
Zidovudine—Muscle spasms—Doxorubicin—testicular cancer	0.000108	0.000574	CcSEcCtD
Zidovudine—Confusional state—Methotrexate—testicular cancer	0.000106	0.000567	CcSEcCtD
Zidovudine—Loss of consciousness—Epirubicin—testicular cancer	0.000106	0.000567	CcSEcCtD
Zidovudine—Cough—Epirubicin—testicular cancer	0.000105	0.000563	CcSEcCtD
Zidovudine—Anaphylactic shock—Methotrexate—testicular cancer	0.000105	0.000562	CcSEcCtD
Zidovudine—Convulsion—Epirubicin—testicular cancer	0.000105	0.000559	CcSEcCtD
Zidovudine—Nausea—Etoposide—testicular cancer	0.000105	0.000558	CcSEcCtD
Zidovudine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000104	0.000553	CcSEcCtD
Zidovudine—Nervous system disorder—Methotrexate—testicular cancer	0.000103	0.000551	CcSEcCtD
Zidovudine—Anaemia—Doxorubicin—testicular cancer	0.000103	0.000551	CcSEcCtD
Zidovudine—Thrombocytopenia—Methotrexate—testicular cancer	0.000103	0.00055	CcSEcCtD
Zidovudine—Arthralgia—Epirubicin—testicular cancer	0.000103	0.000549	CcSEcCtD
Zidovudine—Myalgia—Epirubicin—testicular cancer	0.000103	0.000549	CcSEcCtD
Zidovudine—Chest pain—Epirubicin—testicular cancer	0.000103	0.000549	CcSEcCtD
Zidovudine—Anxiety—Epirubicin—testicular cancer	0.000103	0.000547	CcSEcCtD
Zidovudine—Skin disorder—Methotrexate—testicular cancer	0.000102	0.000546	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000102	0.000545	CcSEcCtD
Zidovudine—Hyperhidrosis—Methotrexate—testicular cancer	0.000102	0.000544	CcSEcCtD
Zidovudine—Discomfort—Epirubicin—testicular cancer	0.000102	0.000542	CcSEcCtD
Zidovudine—Malaise—Doxorubicin—testicular cancer	0.000101	0.000538	CcSEcCtD
Zidovudine—Vertigo—Doxorubicin—testicular cancer	0.0001	0.000536	CcSEcCtD
Zidovudine—Anorexia—Methotrexate—testicular cancer	0.0001	0.000536	CcSEcCtD
Zidovudine—Syncope—Doxorubicin—testicular cancer	0.0001	0.000535	CcSEcCtD
Zidovudine—Leukopenia—Doxorubicin—testicular cancer	0.0001	0.000534	CcSEcCtD
Zidovudine—Confusional state—Epirubicin—testicular cancer	9.95e-05	0.000531	CcSEcCtD
Zidovudine—Anaphylactic shock—Epirubicin—testicular cancer	9.87e-05	0.000526	CcSEcCtD
Zidovudine—Oedema—Epirubicin—testicular cancer	9.87e-05	0.000526	CcSEcCtD
Zidovudine—Loss of consciousness—Doxorubicin—testicular cancer	9.83e-05	0.000524	CcSEcCtD
Zidovudine—Cough—Doxorubicin—testicular cancer	9.76e-05	0.000521	CcSEcCtD
Zidovudine—Shock—Epirubicin—testicular cancer	9.71e-05	0.000518	CcSEcCtD
Zidovudine—Convulsion—Doxorubicin—testicular cancer	9.69e-05	0.000517	CcSEcCtD
Zidovudine—Nervous system disorder—Epirubicin—testicular cancer	9.67e-05	0.000516	CcSEcCtD
Zidovudine—Thrombocytopenia—Epirubicin—testicular cancer	9.66e-05	0.000515	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Methotrexate—testicular cancer	9.6e-05	0.000512	CcSEcCtD
Zidovudine—Skin disorder—Epirubicin—testicular cancer	9.58e-05	0.000511	CcSEcCtD
Zidovudine—Hyperhidrosis—Epirubicin—testicular cancer	9.54e-05	0.000509	CcSEcCtD
Zidovudine—Insomnia—Methotrexate—testicular cancer	9.53e-05	0.000509	CcSEcCtD
Zidovudine—Chest pain—Doxorubicin—testicular cancer	9.52e-05	0.000508	CcSEcCtD
Zidovudine—Myalgia—Doxorubicin—testicular cancer	9.52e-05	0.000508	CcSEcCtD
Zidovudine—Arthralgia—Doxorubicin—testicular cancer	9.52e-05	0.000508	CcSEcCtD
Zidovudine—Anxiety—Doxorubicin—testicular cancer	9.49e-05	0.000506	CcSEcCtD
Zidovudine—Paraesthesia—Methotrexate—testicular cancer	9.47e-05	0.000505	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	9.46e-05	0.000504	CcSEcCtD
Zidovudine—Discomfort—Doxorubicin—testicular cancer	9.41e-05	0.000502	CcSEcCtD
Zidovudine—Anorexia—Epirubicin—testicular cancer	9.4e-05	0.000502	CcSEcCtD
Zidovudine—Dyspnoea—Methotrexate—testicular cancer	9.4e-05	0.000501	CcSEcCtD
Zidovudine—Somnolence—Methotrexate—testicular cancer	9.37e-05	0.0005	CcSEcCtD
Zidovudine—Dyspepsia—Methotrexate—testicular cancer	9.28e-05	0.000495	CcSEcCtD
Zidovudine—Confusional state—Doxorubicin—testicular cancer	9.2e-05	0.000491	CcSEcCtD
Zidovudine—Decreased appetite—Methotrexate—testicular cancer	9.16e-05	0.000489	CcSEcCtD
Zidovudine—Anaphylactic shock—Doxorubicin—testicular cancer	9.13e-05	0.000487	CcSEcCtD
Zidovudine—Oedema—Doxorubicin—testicular cancer	9.13e-05	0.000487	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Methotrexate—testicular cancer	9.1e-05	0.000485	CcSEcCtD
Zidovudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	9.1e-05	0.00399	CbGpPWpGaD
Zidovudine—Fatigue—Methotrexate—testicular cancer	9.09e-05	0.000485	CcSEcCtD
Zidovudine—Pain—Methotrexate—testicular cancer	9.01e-05	0.000481	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.99e-05	0.000479	CcSEcCtD
Zidovudine—Shock—Doxorubicin—testicular cancer	8.98e-05	0.000479	CcSEcCtD
Zidovudine—TERT—Disease—H2AFZ—testicular cancer	8.96e-05	0.00393	CbGpPWpGaD
Zidovudine—Nervous system disorder—Doxorubicin—testicular cancer	8.95e-05	0.000477	CcSEcCtD
Zidovudine—Thrombocytopenia—Doxorubicin—testicular cancer	8.94e-05	0.000477	CcSEcCtD
Zidovudine—Insomnia—Epirubicin—testicular cancer	8.92e-05	0.000476	CcSEcCtD
Zidovudine—Skin disorder—Doxorubicin—testicular cancer	8.87e-05	0.000473	CcSEcCtD
Zidovudine—Paraesthesia—Epirubicin—testicular cancer	8.86e-05	0.000472	CcSEcCtD
Zidovudine—Hyperhidrosis—Doxorubicin—testicular cancer	8.82e-05	0.000471	CcSEcCtD
Zidovudine—Dyspnoea—Epirubicin—testicular cancer	8.8e-05	0.000469	CcSEcCtD
Zidovudine—Somnolence—Epirubicin—testicular cancer	8.77e-05	0.000468	CcSEcCtD
Zidovudine—Anorexia—Doxorubicin—testicular cancer	8.7e-05	0.000464	CcSEcCtD
Zidovudine—Feeling abnormal—Methotrexate—testicular cancer	8.69e-05	0.000463	CcSEcCtD
Zidovudine—Dyspepsia—Epirubicin—testicular cancer	8.68e-05	0.000463	CcSEcCtD
Zidovudine—Gastrointestinal pain—Methotrexate—testicular cancer	8.62e-05	0.00046	CcSEcCtD
Zidovudine—Decreased appetite—Epirubicin—testicular cancer	8.58e-05	0.000457	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Epirubicin—testicular cancer	8.52e-05	0.000454	CcSEcCtD
Zidovudine—Fatigue—Epirubicin—testicular cancer	8.51e-05	0.000454	CcSEcCtD
Zidovudine—Pain—Epirubicin—testicular cancer	8.44e-05	0.00045	CcSEcCtD
Zidovudine—Constipation—Epirubicin—testicular cancer	8.44e-05	0.00045	CcSEcCtD
Zidovudine—Urticaria—Methotrexate—testicular cancer	8.37e-05	0.000447	CcSEcCtD
Zidovudine—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.34e-05	0.00366	CbGpPWpGaD
Zidovudine—CYP2C8—Biological oxidations—HPGDS—testicular cancer	8.34e-05	0.00366	CbGpPWpGaD
Zidovudine—Body temperature increased—Methotrexate—testicular cancer	8.33e-05	0.000444	CcSEcCtD
Zidovudine—Abdominal pain—Methotrexate—testicular cancer	8.33e-05	0.000444	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	8.32e-05	0.000444	CcSEcCtD
Zidovudine—Insomnia—Doxorubicin—testicular cancer	8.26e-05	0.00044	CcSEcCtD
Zidovudine—TK1—Metabolism—STK11—testicular cancer	8.25e-05	0.00362	CbGpPWpGaD
Zidovudine—TERT—Disease—KITLG—testicular cancer	8.24e-05	0.00362	CbGpPWpGaD
Zidovudine—Paraesthesia—Doxorubicin—testicular cancer	8.2e-05	0.000437	CcSEcCtD
Zidovudine—Dyspnoea—Doxorubicin—testicular cancer	8.14e-05	0.000434	CcSEcCtD
Zidovudine—Feeling abnormal—Epirubicin—testicular cancer	8.13e-05	0.000434	CcSEcCtD
Zidovudine—Somnolence—Doxorubicin—testicular cancer	8.12e-05	0.000433	CcSEcCtD
Zidovudine—Gastrointestinal pain—Epirubicin—testicular cancer	8.07e-05	0.00043	CcSEcCtD
Zidovudine—Dyspepsia—Doxorubicin—testicular cancer	8.04e-05	0.000429	CcSEcCtD
Zidovudine—Decreased appetite—Doxorubicin—testicular cancer	7.94e-05	0.000423	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.88e-05	0.00042	CcSEcCtD
Zidovudine—Fatigue—Doxorubicin—testicular cancer	7.87e-05	0.00042	CcSEcCtD
Zidovudine—Urticaria—Epirubicin—testicular cancer	7.84e-05	0.000418	CcSEcCtD
Zidovudine—Constipation—Doxorubicin—testicular cancer	7.81e-05	0.000416	CcSEcCtD
Zidovudine—Pain—Doxorubicin—testicular cancer	7.81e-05	0.000416	CcSEcCtD
Zidovudine—Abdominal pain—Epirubicin—testicular cancer	7.8e-05	0.000416	CcSEcCtD
Zidovudine—Body temperature increased—Epirubicin—testicular cancer	7.8e-05	0.000416	CcSEcCtD
Zidovudine—Asthenia—Methotrexate—testicular cancer	7.56e-05	0.000403	CcSEcCtD
Zidovudine—Feeling abnormal—Doxorubicin—testicular cancer	7.52e-05	0.000401	CcSEcCtD
Zidovudine—Gastrointestinal pain—Doxorubicin—testicular cancer	7.46e-05	0.000398	CcSEcCtD
Zidovudine—Pruritus—Methotrexate—testicular cancer	7.46e-05	0.000398	CcSEcCtD
Zidovudine—CYP2C19—Biological oxidations—HPGDS—testicular cancer	7.44e-05	0.00327	CbGpPWpGaD
Zidovudine—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	7.31e-05	0.00321	CbGpPWpGaD
Zidovudine—Urticaria—Doxorubicin—testicular cancer	7.25e-05	0.000387	CcSEcCtD
Zidovudine—Body temperature increased—Doxorubicin—testicular cancer	7.22e-05	0.000385	CcSEcCtD
Zidovudine—Abdominal pain—Doxorubicin—testicular cancer	7.22e-05	0.000385	CcSEcCtD
Zidovudine—Diarrhoea—Methotrexate—testicular cancer	7.21e-05	0.000385	CcSEcCtD
Zidovudine—Asthenia—Epirubicin—testicular cancer	7.08e-05	0.000377	CcSEcCtD
Zidovudine—Pruritus—Epirubicin—testicular cancer	6.98e-05	0.000372	CcSEcCtD
Zidovudine—Dizziness—Methotrexate—testicular cancer	6.97e-05	0.000372	CcSEcCtD
Zidovudine—CYP2C9—Biological oxidations—HPGDS—testicular cancer	6.79e-05	0.00298	CbGpPWpGaD
Zidovudine—Diarrhoea—Epirubicin—testicular cancer	6.75e-05	0.00036	CcSEcCtD
Zidovudine—Vomiting—Methotrexate—testicular cancer	6.7e-05	0.000357	CcSEcCtD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	6.68e-05	0.00293	CbGpPWpGaD
Zidovudine—Rash—Methotrexate—testicular cancer	6.65e-05	0.000354	CcSEcCtD
Zidovudine—Dermatitis—Methotrexate—testicular cancer	6.64e-05	0.000354	CcSEcCtD
Zidovudine—Headache—Methotrexate—testicular cancer	6.6e-05	0.000352	CcSEcCtD
Zidovudine—Asthenia—Doxorubicin—testicular cancer	6.55e-05	0.000349	CcSEcCtD
Zidovudine—Dizziness—Epirubicin—testicular cancer	6.52e-05	0.000348	CcSEcCtD
Zidovudine—Pruritus—Doxorubicin—testicular cancer	6.46e-05	0.000344	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—H2AFZ—testicular cancer	6.27e-05	0.00275	CbGpPWpGaD
Zidovudine—Vomiting—Epirubicin—testicular cancer	6.27e-05	0.000335	CcSEcCtD
Zidovudine—Nausea—Methotrexate—testicular cancer	6.26e-05	0.000334	CcSEcCtD
Zidovudine—Diarrhoea—Doxorubicin—testicular cancer	6.25e-05	0.000333	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—STK11—testicular cancer	6.24e-05	0.00274	CbGpPWpGaD
Zidovudine—Rash—Epirubicin—testicular cancer	6.22e-05	0.000332	CcSEcCtD
Zidovudine—Dermatitis—Epirubicin—testicular cancer	6.21e-05	0.000331	CcSEcCtD
Zidovudine—Headache—Epirubicin—testicular cancer	6.18e-05	0.00033	CcSEcCtD
Zidovudine—TERT—Disease—FGFR3—testicular cancer	6.13e-05	0.00269	CbGpPWpGaD
Zidovudine—Dizziness—Doxorubicin—testicular cancer	6.04e-05	0.000322	CcSEcCtD
Zidovudine—Nausea—Epirubicin—testicular cancer	5.86e-05	0.000313	CcSEcCtD
Zidovudine—Vomiting—Doxorubicin—testicular cancer	5.8e-05	0.00031	CcSEcCtD
Zidovudine—TERT—Signaling Pathways—KITLG—testicular cancer	5.77e-05	0.00253	CbGpPWpGaD
Zidovudine—Rash—Doxorubicin—testicular cancer	5.76e-05	0.000307	CcSEcCtD
Zidovudine—Dermatitis—Doxorubicin—testicular cancer	5.75e-05	0.000307	CcSEcCtD
Zidovudine—Headache—Doxorubicin—testicular cancer	5.72e-05	0.000305	CcSEcCtD
Zidovudine—TERT—Disease—KIT—testicular cancer	5.62e-05	0.00247	CbGpPWpGaD
Zidovudine—Nausea—Doxorubicin—testicular cancer	5.42e-05	0.000289	CcSEcCtD
Zidovudine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	4.85e-05	0.00213	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—HPGDS—testicular cancer	4.52e-05	0.00198	CbGpPWpGaD
Zidovudine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	4.48e-05	0.00196	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—FGFR3—testicular cancer	4.29e-05	0.00188	CbGpPWpGaD
Zidovudine—ABCC5—Disease—H2AFZ—testicular cancer	3.94e-05	0.00173	CbGpPWpGaD
Zidovudine—TERT—Signaling Pathways—KIT—testicular cancer	3.94e-05	0.00173	CbGpPWpGaD
Zidovudine—ABCC5—Disease—KITLG—testicular cancer	3.63e-05	0.00159	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—HPGDS—testicular cancer	3.33e-05	0.00146	CbGpPWpGaD
Zidovudine—ABCC5—Metabolism—STK11—testicular cancer	3.28e-05	0.00144	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.2e-05	0.00141	CbGpPWpGaD
Zidovudine—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.18e-05	0.0014	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.86e-05	0.00125	CbGpPWpGaD
Zidovudine—ABCC5—Disease—FGFR3—testicular cancer	2.7e-05	0.00118	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.61e-05	0.00114	CbGpPWpGaD
Zidovudine—ABCC5—Disease—KIT—testicular cancer	2.48e-05	0.00109	CbGpPWpGaD
Zidovudine—UGT2B7—Metabolism—STK11—testicular cancer	2.42e-05	0.00106	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—HPGDS—testicular cancer	2.3e-05	0.00101	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—HPGDS—testicular cancer	2.27e-05	0.000998	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—HPGDS—testicular cancer	2.09e-05	0.000916	CbGpPWpGaD
Zidovudine—ABCG2—Metabolism—STK11—testicular cancer	1.67e-05	0.000733	CbGpPWpGaD
Zidovudine—SLC22A2—Metabolism—STK11—testicular cancer	1.65e-05	0.000725	CbGpPWpGaD
Zidovudine—CYP2A6—Metabolism—STK11—testicular cancer	1.52e-05	0.000666	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—HPGDS—testicular cancer	1.43e-05	0.000626	CbGpPWpGaD
Zidovudine—ALB—Metabolism—HPGDS—testicular cancer	1.42e-05	0.000622	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—HPGDS—testicular cancer	1.27e-05	0.000559	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—HPGDS—testicular cancer	1.24e-05	0.000545	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—HPGDS—testicular cancer	1.16e-05	0.00051	CbGpPWpGaD
Zidovudine—CYP2C8—Metabolism—STK11—testicular cancer	1.04e-05	0.000455	CbGpPWpGaD
Zidovudine—ALB—Metabolism—STK11—testicular cancer	1.03e-05	0.000452	CbGpPWpGaD
Zidovudine—CYP2C19—Metabolism—STK11—testicular cancer	9.25e-06	0.000406	CbGpPWpGaD
Zidovudine—ABCB1—Metabolism—STK11—testicular cancer	9.03e-06	0.000396	CbGpPWpGaD
Zidovudine—CYP2C9—Metabolism—STK11—testicular cancer	8.43e-06	0.00037	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—HPGDS—testicular cancer	7.65e-06	0.000336	CbGpPWpGaD
Zidovudine—CYP3A4—Metabolism—STK11—testicular cancer	5.56e-06	0.000244	CbGpPWpGaD
